{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:46Z","timestamp":1790958586625,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["8226010026"],"award-info":[{"award-number":["8226010026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Project of Gansu Province","award":["22JR11RA053"],"award-info":[{"award-number":["22JR11RA053"]}]},{"name":"The \u201cCuiYing postgraduate tutor\u201d training program of Lanzhou University Second Hospital","award":["201710"],"award-info":[{"award-number":["201710"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05974-8","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:02:51Z","timestamp":1724824971000},"page":"4401-4412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in CD5+ diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Ningning","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"2","key":"5974_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146\u2013171. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"5974_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccell.2022.01.013","volume":"40","author":"P-P Xu","year":"2022","unstructured":"Xu P-P, Huo Y-J, Zhao W-L (2022) All roads lead to targeted diffuse large B-cell lymphoma approaches. Cancer Cell 40(2):131\u2013133. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.013","journal-title":"Cancer Cell"},{"key":"5974_CR3","doi-asserted-by":"publisher","unstructured":"Dabrowska-Iwanicka AP, Nowakowski GS (2023) DLBCL: Who is high risk and how should treatment be optimized? Blood. https:\/\/doi.org\/10.1182\/blood.2023020779","DOI":"10.1182\/blood.2023020779"},{"key":"5974_CR4","volume-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon","edition":"4"},{"key":"5974_CR5","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC, Lyon"},{"issue":"1","key":"5974_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22\u201332. https:\/\/doi.org\/10.1182\/blood-2014-05-577189","journal-title":"Blood"},{"issue":"8","key":"5974_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3324\/haematol.12810","volume":"93","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R et al (2008) De novo CD5\u2009+\u2009diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93(8):1195\u20131202. https:\/\/doi.org\/10.3324\/haematol.12810","journal-title":"Haematologica"},{"issue":"3","key":"5974_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood.v99.3.815","volume":"99","author":"M Yamaguchi","year":"2002","unstructured":"Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T et al (2002) De novo CD5\u2009+\u2009diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99(3):815\u2013821. https:\/\/doi.org\/10.1182\/blood.v99.3.815","journal-title":"Blood"},{"issue":"5","key":"5974_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00428-015-1845-1","volume":"467","author":"W-Y Chuang","year":"2015","unstructured":"Chuang W-Y, Chang H, Shih L-Y, Wang P-N, Chang Y-S, Lin T-L et al (2015) CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch 467(5):571\u2013582. https:\/\/doi.org\/10.1007\/s00428-015-1845-1","journal-title":"Virchows Arch"},{"issue":"11","key":"5974_CR10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/annonc\/mdn392","volume":"19","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y et al (2008) CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 19(11):1921\u20131926. https:\/\/doi.org\/10.1093\/annonc\/mdn392","journal-title":"Ann Oncol"},{"issue":"12","key":"5974_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s002510000235","volume":"51","author":"O Padilla","year":"2000","unstructured":"Padilla O, Calvo J, Vil\u00e0 JM, Arman M, Gimferrer I, Places L et al (2000) Genomic organization of the human CD5 gene. Immunogenetics 51(12):993\u20131001. https:\/\/doi.org\/10.1007\/s002510000235","journal-title":"Immunogenetics"},{"issue":"7","key":"5974_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/s0167-5699(99)01476-0","volume":"20","author":"P Youinou","year":"1999","unstructured":"Youinou P, Jamin C, Lydyard PM (1999) CD5 expression in human B-cell populations. Immunol Today 20(7):312\u2013316. https:\/\/doi.org\/10.1016\/s0167-5699(99)01476-0","journal-title":"Immunol Today"},{"key":"5974_CR13","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.3389\/fimmu.2018.02900","volume":"9","author":"G Voisinne","year":"2018","unstructured":"Voisinne G, Gonzalez de Peredo A, Roncagalli R (2018) CD5, an Undercover Regulator of TCR Signaling. Front Immunol 9:2900. https:\/\/doi.org\/10.3389\/fimmu.2018.02900","journal-title":"Front Immunol"},{"issue":"6","key":"5974_CR14","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1084\/jem.168.6.1979","volume":"168","author":"SE Burastero","year":"1988","unstructured":"Burastero SE, Casali P, Wilder RL, Notkins AL (1988) Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5\u2009+\u2009B cells from patients with rheumatoid arthritis. J Exp Med 168(6):1979\u20131992. https:\/\/doi.org\/10.1084\/jem.168.6.1979","journal-title":"J Exp Med"},{"issue":"4797","key":"5974_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1126\/science.3105057","volume":"236","author":"RR Hardy","year":"1987","unstructured":"Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T (1987) Rheumatoid factor secretion from human Leu-1\u2009+\u2009B cells. Sci (New York NY) 236(4797):81\u201383. https:\/\/doi.org\/10.1126\/science.3105057","journal-title":"Sci (New York NY)"},{"key":"5974_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/nyas.12768","volume":"1362","author":"K Hayakawa","year":"2015","unstructured":"Hayakawa K, Formica AM, Colombo MJ, Ichikawa D, Shinton SA, Brill-Dashoff J et al (2015) B cells generated by B-1 development can progress to chronic lymphocytic leukemia. Ann N Y Acad Sci 1362:250\u2013255. https:\/\/doi.org\/10.1111\/nyas.12768","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5974_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4049\/jimmunol.136.2.505","volume":"136","author":"JH Antin","year":"1986","unstructured":"Antin JH, Emerson SG, Martin P, Gadol N, Ault KA (1986) Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol 136(2):505\u2013510","journal-title":"J Immunol"},{"issue":"3","key":"5974_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1309\/AJCP58FETFGLCKKW","volume":"131","author":"AM Maeshima","year":"2009","unstructured":"Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim S-W, Watanabe T et al (2009) Secondary CD5\u2009+\u2009diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 131(3):339\u2013346. https:\/\/doi.org\/10.1309\/AJCP58FETFGLCKKW","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"5974_CR19","doi-asserted-by":"publisher","first-page":"e782","DOI":"10.1016\/j.clml.2020.05.003","volume":"20","author":"Y Xu","year":"2020","unstructured":"Xu Y, Sun W, Li F (2020) De Novo CD5\u2009+\u2009diffuse large B-Cell lymphoma: Biology, mechanism, and treatment advances. Clin Lymphoma Myeloma Leuk 20(10):e782\u2013e790. https:\/\/doi.org\/10.1016\/j.clml.2020.05.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"5974_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4049\/jimmunol.168.1.232","volume":"168","author":"H Gary-Gouy","year":"2002","unstructured":"Gary-Gouy H, Harriague J, Dalloul A, Donnadieu E, Bismuth G (2002) CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J Immunol 168(1):232\u2013239. https:\/\/doi.org\/10.4049\/jimmunol.168.1.232","journal-title":"J Immunol"},{"key":"5974_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-065x.2000.00605.x","volume":"176","author":"T Kurosaki","year":"2000","unstructured":"Kurosaki T, Maeda A, Ishiai M, Hashimoto A, Inabe K, Takata M (2000) Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev 176:19\u201329. https:\/\/doi.org\/10.1034\/j.1600-065x.2000.00605.x","journal-title":"Immunol Rev"},{"issue":"14","key":"5974_CR22","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/sj.onc.1202552","volume":"18","author":"A Maeda","year":"1999","unstructured":"Maeda A, Scharenberg AM, Tsukada S, Bolen JB, Kinet JP, Kurosaki T (1999) Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene 18(14):2291\u20132297. https:\/\/doi.org\/10.1038\/sj.onc.1202552","journal-title":"Oncogene"},{"issue":"3","key":"5974_CR23","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.4049\/jimmunol.165.3.1344","volume":"165","author":"K Mizuno","year":"2000","unstructured":"Mizuno K, Tagawa Y, Mitomo K, Arimura Y, Hatano N, Katagiri T et al (2000) Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates b cell linker protein\/SH2 domain leukocyte protein of 65\u00a0kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells. J Immunol 165(3):1344\u20131351. https:\/\/doi.org\/10.4049\/jimmunol.165.3.1344","journal-title":"J Immunol"},{"issue":"4","key":"5974_CR24","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1128\/MCB.19.4.2903","volume":"19","author":"JJ Perez-Villar","year":"1999","unstructured":"Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB (1999) CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 19(4):2903\u20132912. https:\/\/doi.org\/10.1128\/MCB.19.4.2903","journal-title":"Mol Cell Biol"},{"issue":"12","key":"5974_CR25","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","volume":"119","author":"M Gupta","year":"2012","unstructured":"Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G et al (2012) Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119(12):2844\u20132853. https:\/\/doi.org\/10.1182\/blood-2011-10-388538","journal-title":"Blood"},{"issue":"17","key":"5974_CR26","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","volume":"132","author":"L Li","year":"2018","unstructured":"Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M et al (2018) B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma. Blood 132(17):1805\u20131817. https:\/\/doi.org\/10.1182\/blood-2018-03-841015","journal-title":"Blood"},{"issue":"6","key":"5974_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1189\/jlb.0803363","volume":"74","author":"A Mohamedali","year":"2003","unstructured":"Mohamedali A, Soeiro I, Lea NC, Glassford J, Banerji L, Mufti GJ et al (2003) Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol 74(6):1139\u20131143. https:\/\/doi.org\/10.1189\/jlb.0803363","journal-title":"J Leukoc Biol"},{"issue":"8","key":"5974_CR28","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.18632\/oncotarget.3479","volume":"6","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C et al (2015) Clinical and biological significance of de novo CD5\u2009+\u2009diffuse large B-cell lymphoma in western countries. Oncotarget 6(8):5615\u20135633. https:\/\/doi.org\/10.18632\/oncotarget.3479","journal-title":"Oncotarget"},{"issue":"12","key":"5974_CR29","doi-asserted-by":"publisher","first-page":"e115249","DOI":"10.1371\/journal.pone.0115249","volume":"9","author":"K Huang","year":"2014","unstructured":"Huang K, Kiefer C, Kamal A (2014) Novel role for NFAT3 in ERK-mediated regulation of CXCR4. PLoS ONE 9(12):e115249. https:\/\/doi.org\/10.1371\/journal.pone.0115249","journal-title":"PLoS ONE"},{"key":"5974_CR30","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3389\/fimmu.2017.01773","volume":"8","author":"H Shaim","year":"2017","unstructured":"Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P et al (2017) The CXCR4-STAT3-IL-10 pathway controls the Immunoregulatory function of chronic lymphocytic leukemia and is modulated by Lenalidomide. Front Immunol 8:1773. https:\/\/doi.org\/10.3389\/fimmu.2017.01773","journal-title":"Front Immunol"},{"issue":"3","key":"5974_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.4446","volume":"235","author":"MJ Moreno","year":"2015","unstructured":"Moreno MJ, Bosch R, Dieguez-Gonzalez R, Novelli S, Mozos A, Gallardo A et al (2015) CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol 235(3):445\u2013455. https:\/\/doi.org\/10.1002\/path.4446","journal-title":"J Pathol"},{"issue":"6","key":"5974_CR32","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1080\/10428194.2017.1379077","volume":"59","author":"Z-Z Xu","year":"2018","unstructured":"Xu Z-Z, Shen J-K, Zhao S-Q, Li J-M (2018) Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 59(6):1451\u20131460. https:\/\/doi.org\/10.1080\/10428194.2017.1379077","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"5974_CR33","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa032520","volume":"350","author":"IS Lossos","year":"2004","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D et al (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350(18):1828\u20131837. https:\/\/doi.org\/10.1056\/NEJMoa032520","journal-title":"N Engl J Med"},{"issue":"1","key":"5974_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"issue":"6","key":"5974_CR35","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","volume":"24","author":"J Iqbal","year":"2006","unstructured":"Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A et al (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24(6):961\u2013968. https:\/\/doi.org\/10.1200\/JCO.2005.03.4264","journal-title":"J Clin Oncol"},{"issue":"26","key":"5974_CR36","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","volume":"117","author":"G Salles","year":"2011","unstructured":"Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P et al (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117(26):7070\u20137078. https:\/\/doi.org\/10.1182\/blood-2011-04-345256","journal-title":"Blood"},{"issue":"3","key":"5974_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5114\/pjp.2016.63775","volume":"67","author":"N Wo\u017anialis","year":"2016","unstructured":"Wo\u017anialis N, Gierej B, Pop\u0142awska L, Ziarkiewicz M, Kulczycka E, Ziarkiewicz-Wr\u00f3blewska B (2016) A rare CD5-positive subgroup of diffuse large B-cell lymphoma - clinical, morphological and immunophenotypic features in Polish patients. Pol J Pathol 67(3):235\u2013243. https:\/\/doi.org\/10.5114\/pjp.2016.63775","journal-title":"Pol J Pathol"},{"issue":"10","key":"5974_CR38","doi-asserted-by":"publisher","first-page":"e0224247","DOI":"10.1371\/journal.pone.0224247","volume":"14","author":"HY Na","year":"2019","unstructured":"Na HY, Choe J-Y, Shin SA, Kim H-J, Han JH, Kim HK et al (2019) Characteristics of CD5-positive diffuse large B-cell lymphoma among koreans: high incidence of BCL2 and MYC double-expressors. PLoS ONE 14(10):e0224247. https:\/\/doi.org\/10.1371\/journal.pone.0224247","journal-title":"PLoS ONE"},{"issue":"10","key":"5974_CR39","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/annonc\/mdq057","volume":"21","author":"N Niitsu","year":"2010","unstructured":"Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 21(10):2069\u20132074. https:\/\/doi.org\/10.1093\/annonc\/mdq057","journal-title":"Ann Oncol"},{"issue":"4","key":"5974_CR40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hon.2657","volume":"37","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X et al (2019) CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol 37(4):360\u2013367. https:\/\/doi.org\/10.1002\/hon.2657","journal-title":"Hematol Oncol"},{"issue":"1","key":"5974_CR41","doi-asserted-by":"publisher","first-page":"e23921","DOI":"10.1016\/j.heliyon.2023.e23921","volume":"10","author":"J-W Li","year":"2024","unstructured":"Li J-W, Deng C, Zhou X-Y, Deng R (2024) The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma. NOS Heliyon 10(1):e23921. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23921","journal-title":"NOS Heliyon"},{"issue":"2","key":"5974_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/life13020521","volume":"13","author":"AM Ross","year":"2023","unstructured":"Ross AM, Leahy CI, Neylon F, Steigerova J, Flodr P, Navratilova M et al (2023) Epstein-Barr Virus and the pathogenesis of diffuse large B-Cell lymphoma. Life (Basel) 13(2):521. https:\/\/doi.org\/10.3390\/life13020521","journal-title":"Life (Basel)"},{"key":"5974_CR43","doi-asserted-by":"publisher","first-page":"104326","DOI":"10.1016\/j.yexmp.2019.104326","volume":"112","author":"T-X Lu","year":"2020","unstructured":"Lu T-X, Wu S, Zhou X-Y, Zhang Y, Hong T-T, Cai D-Y et al (2020) CD5\u2009+\u2009MYC\u2009+\u2009predicts worse prognosis in diffuse large B-cell lymphoma. Exp Mol Pathol 112:104326. https:\/\/doi.org\/10.1016\/j.yexmp.2019.104326","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"5974_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/gcc.20127","volume":"42","author":"T Yoshioka","year":"2005","unstructured":"Yoshioka T, Miura I, Kume M, Takahashi N, Okamoto M, Ichinohasama R et al (2005) Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 42(2):149\u2013157. https:\/\/doi.org\/10.1002\/gcc.20127","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"5974_CR45","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood.v98.12.3479","volume":"98","author":"JA Martinez-Climent","year":"2001","unstructured":"Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Benet I et al (2001) Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 98(12):3479\u20133482. https:\/\/doi.org\/10.1182\/blood.v98.12.3479","journal-title":"Blood"},{"issue":"4","key":"5974_CR46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2141.1999.01239.x","volume":"104","author":"C Shimazaki","year":"1999","unstructured":"Shimazaki C, Inaba T, Shimura K, Okamoto A, Takahashi R, Hirai H et al (1999) B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Br J Haematol 104(4):672\u2013679. https:\/\/doi.org\/10.1111\/j.1365-2141.1999.01239.x","journal-title":"Br J Haematol"},{"issue":"2","key":"5974_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF02982007","volume":"74","author":"N Takahashi","year":"2001","unstructured":"Takahashi N, Chubachi A, Kume M, Hatano Y, Komatsuda A, Kawabata Y et al (2001) A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 74(2):209\u2013213. https:\/\/doi.org\/10.1007\/BF02982007","journal-title":"Int J Hematol"},{"issue":"3","key":"5974_CR48","first-page":"826","volume":"111","author":"T Murase","year":"2000","unstructured":"Murase T, Nakamura S, Kawauchi K, Matsuzaki H, Sakai C, Inaba T et al (2000) An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111(3):826\u2013834","journal-title":"Br J Haematol"},{"issue":"9","key":"5974_CR49","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2005-05-2013","volume":"106","author":"F Rubio-Moscardo","year":"2005","unstructured":"Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A et al (2005) Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106(9):3214\u20133222. https:\/\/doi.org\/10.1182\/blood-2005-05-2013","journal-title":"Blood"},{"issue":"4","key":"5974_CR50","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.15001","volume":"183","author":"Y Mishima","year":"2018","unstructured":"Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y et al (2018) Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5\u2009+\u2009DLBCL. Br J Haematol 183(4):661\u2013664. https:\/\/doi.org\/10.1111\/bjh.15001","journal-title":"Br J Haematol"},{"issue":"8","key":"5974_CR51","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1038\/bcj.2015.69","volume":"5","author":"AJ Novak","year":"2015","unstructured":"Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS et al (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 5(8):e346. https:\/\/doi.org\/10.1038\/bcj.2015.69","journal-title":"Blood Cancer J"},{"issue":"17","key":"5974_CR52","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-03-4056","volume":"64","author":"H Tagawa","year":"2004","unstructured":"Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y et al (2004) Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 64(17):5948\u20135955. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-4056","journal-title":"Cancer Res"},{"issue":"9","key":"5974_CR53","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2006.00267.x","volume":"97","author":"M Suguro","year":"2006","unstructured":"Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H et al (2006) Expression profiling analysis of the CD5\u2009+\u2009diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 97(9):868\u2013874. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00267.x","journal-title":"Cancer Sci"},{"issue":"1","key":"5974_CR54","first-page":"60","volume":"63","author":"T Kobayashi","year":"2003","unstructured":"Kobayashi T, Yamaguchi M, Kim S, Morikawa J, Ogawa S, Ueno S et al (2003) Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5\u2009+\u2009and CD5- diffuse large B-cell lymphomas. Cancer Res 63(1):60\u201366","journal-title":"Cancer Res"},{"key":"5974_CR55","doi-asserted-by":"publisher","first-page":"151886","DOI":"10.1016\/j.anndiagpath.2021.151886","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Binshen O, Zhang Z, Yi H, Zhang W, Liu Q et al (2022) De Novo CD5-positive diffuse large B-cell lymphoma: a genomic profiling study and prognostic analysis of 46 patients. Ann Diagn Pathol 58:151886. https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151886","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"5974_CR56","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/cncr.30404","volume":"123","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H et al (2017) MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer 123(7):1166\u20131173. https:\/\/doi.org\/10.1002\/cncr.30404","journal-title":"Cancer"},{"issue":"5","key":"5974_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11899-018-0467-5","volume":"13","author":"J Rhodes","year":"2018","unstructured":"Rhodes J, Landsburg DJ (2018) Small-molecule inhibitors for the treatment of diffuse large B cell lymphoma. Curr Hematol Malig Rep 13(5):356\u2013368. https:\/\/doi.org\/10.1007\/s11899-018-0467-5","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"5974_CR58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922\u2013926. https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"issue":"4","key":"5974_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.23.01574","volume":"42","author":"A Cooper","year":"2024","unstructured":"Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song JY, Lytle A et al (2024) CD5 gene signature identifies diffuse large B-Cell Lymphomas Sensitive to Bruton\u2019s tyrosine kinase inhibition. J Clin Oncol 42(4):467\u2013480. https:\/\/doi.org\/10.1200\/JCO.23.01574","journal-title":"J Clin Oncol"},{"issue":"7","key":"5974_CR60","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","volume":"22","author":"K Miyazaki","year":"2011","unstructured":"Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N et al (2011) CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22(7):1601\u20131607. https:\/\/doi.org\/10.1093\/annonc\/mdq627","journal-title":"Ann Oncol"},{"issue":"2","key":"5974_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/10428194.2019.1663418","volume":"61","author":"B Hu","year":"2020","unstructured":"Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE et al (2020) De novo CD5\u2009+\u2009diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in Rituximab era. Leuk Lymphoma 61(2):328\u2013336. https:\/\/doi.org\/10.1080\/10428194.2019.1663418","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5974_CR62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2013a survey of 1693 patients treated in protocols of the German High-Grade Non-hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149\u2013157. https:\/\/doi.org\/10.1093\/annonc\/mdl327","journal-title":"Ann Oncol"},{"issue":"1","key":"5974_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/annonc\/mdh013","volume":"15","author":"P Feugier","year":"2004","unstructured":"Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M et al (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of Rituximab. Ann Oncol 15(1):129\u2013133. https:\/\/doi.org\/10.1093\/annonc\/mdh013","journal-title":"Ann Oncol"},{"issue":"4","key":"5974_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12308-022-00523-6","volume":"15","author":"U Demirci","year":"2022","unstructured":"Demirci U, Kirkizlar HO, \u00dcmit EG, G\u00fcrsoy V, Pinar IE, \u00d6zkalemkas F et al (2022) CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study. J Hematopathology 15(4):203\u2013213. https:\/\/doi.org\/10.1007\/s12308-022-00523-6","journal-title":"J Hematopathology"},{"issue":"1","key":"5974_CR65","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/16078454.2019.1614289","volume":"24","author":"H Tang","year":"2019","unstructured":"Tang H, Zhou H, Wei J, Liu H, Qian W, Chen X (2019) Clinicopathologic significance and therapeutic implication of de novo CD5\u2009+\u2009diffuse large B-cell lymphoma. Hematology 24(1):446\u2013454. https:\/\/doi.org\/10.1080\/16078454.2019.1614289","journal-title":"Hematology"},{"issue":"11","key":"5974_CR66","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/PAS.0000000000001957","volume":"46","author":"W Sang","year":"2022","unstructured":"Sang W, Ma Y, Wang X, Ma Y, Shen Z, Gu W et al (2022) Clinicopathologic features and genomic signature of De Novo CD5\u2009+\u2009diffuse large B-Cell lymphoma: a Multicenter Collaborative Study. Am J Surg Pathol 46(11):1533\u20131544. https:\/\/doi.org\/10.1097\/PAS.0000000000001957","journal-title":"Am J Surg Pathol"},{"key":"5974_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/BLCTT.S216292","volume":"9","author":"F Zhang","year":"2019","unstructured":"Zhang F, Li L, Zhang L, Li X, Fu X, Wang X et al (2019) Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab\/R-CHOP regimens. Blood Lymphat Cancer 9:33\u201343. https:\/\/doi.org\/10.2147\/BLCTT.S216292","journal-title":"Blood Lymphat Cancer"},{"issue":"9","key":"5974_CR68","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1002\/cam4.1674","volume":"7","author":"X-B Ma","year":"2018","unstructured":"Ma X-B, Zhong Y-P, Zheng Y, Jiang J, Wang Y-P (2018) Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med 7(9):4284\u20134295. https:\/\/doi.org\/10.1002\/cam4.1674","journal-title":"Cancer Med"},{"issue":"4","key":"5974_CR69","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ejh.12847","volume":"98","author":"B Thakral","year":"2017","unstructured":"Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G et al (2017) Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol 98(4):415\u2013421. https:\/\/doi.org\/10.1111\/ejh.12847","journal-title":"Eur J Haematol"},{"issue":"6","key":"5974_CR70","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MCA Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I et al (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 16(6):704\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(15)70128-2","journal-title":"Lancet Oncol"},{"issue":"5","key":"5974_CR71","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K et al (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 6(5):e254\u2013e265. https:\/\/doi.org\/10.1016\/S2352-3026(19)30026-2","journal-title":"Lancet Haematol"},{"issue":"4","key":"5974_CR72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"5","key":"5974_CR73","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3324\/haematol.2011.056531","volume":"97","author":"WH Wilson","year":"2012","unstructured":"Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Martin SE et al (2012) A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5):758\u2013765. https:\/\/doi.org\/10.3324\/haematol.2011.056531","journal-title":"Haematologica"},{"issue":"16","key":"5974_CR74","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","volume":"26","author":"WH Wilson","year":"2008","unstructured":"Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM et al (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26(16):2717\u20132724. https:\/\/doi.org\/10.1200\/JCO.2007.13.1391","journal-title":"J Clin Oncol"},{"issue":"9","key":"5974_CR75","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3324\/haematol.2019.231076","volume":"105","author":"K Miyazaki","year":"2020","unstructured":"Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T et al (2020) DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica 105(9):2308\u20132315. https:\/\/doi.org\/10.3324\/haematol.2019.231076","journal-title":"Haematologica"},{"issue":"21","key":"5974_CR76","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD et al (2019) Dose-adjusted EPOCH-R compared with R-CHOP as Frontline therapy for diffuse large B-Cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303. J Clin Oncol 37(21):1790\u20131799. https:\/\/doi.org\/10.1200\/JCO.18.01994","journal-title":"J Clin Oncol"},{"issue":"13","key":"5974_CR77","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S1470-2045(11)70140-1","volume":"12","author":"R Kridel","year":"2011","unstructured":"Kridel R, Dietrich P-Y (2011) Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 12(13):1258\u20131266. https:\/\/doi.org\/10.1016\/S1470-2045(11)70140-1","journal-title":"Lancet Oncol"},{"issue":"8","key":"5974_CR78","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00277-003-0679-0","volume":"82","author":"J Barretina","year":"2003","unstructured":"Barretina J, Junc\u00e0 J, Llano A, Guti\u00e9rrez A, Flores A, Blanco J et al (2003) CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 82(8):500\u2013505. https:\/\/doi.org\/10.1007\/s00277-003-0679-0","journal-title":"Ann Hematol"},{"issue":"3","key":"5974_CR79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41416-021-01434-6","volume":"125","author":"J Cai","year":"2021","unstructured":"Cai J, Tian X, Ma S, Zhong L, Li W, Wang L et al (2021) A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the Rituximab era: a multi-institutional cohort study. Br J Cancer 125(3):402\u2013412. https:\/\/doi.org\/10.1038\/s41416-021-01434-6","journal-title":"Br J Cancer"},{"issue":"16","key":"5974_CR80","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2021014506","volume":"139","author":"MR Wilson","year":"2022","unstructured":"Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S et al (2022) Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood 139(16):2499\u20132511. https:\/\/doi.org\/10.1182\/blood.2021014506","journal-title":"Blood"},{"issue":"3","key":"5974_CR81","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek M-K et al (2022) Single-route CNS prophylaxis for aggressive non-hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood 139(3):413\u2013423. https:\/\/doi.org\/10.1182\/blood.2021012888","journal-title":"Blood"},{"key":"5974_CR82","doi-asserted-by":"publisher","unstructured":"Lewis KL, Jakobsen LH, Villa D, Bobillo S, Smedby KE, Savage KJ et al (2021) High-dose methotrexate is not Associated with reduction in CNS relapse in patients with aggressive B-Cell lymphoma: an International Retrospective Study of 2300 high-risk patients. Blood 138. https:\/\/doi.org\/10.1182\/blood-2021-146737","DOI":"10.1182\/blood-2021-146737"},{"issue":"4","key":"5974_CR83","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ajh.24299","volume":"91","author":"L Alinari","year":"2016","unstructured":"Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G et al (2016) De novo CD5\u2009+\u2009diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol 91(4):395\u2013399. https:\/\/doi.org\/10.1002\/ajh.24299","journal-title":"Am J Hematol"},{"issue":"4","key":"5974_CR84","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"L-H Zhang","year":"2013","unstructured":"Zhang L-H, Kosek J, Wang M, Heise C, Schafer PH, Chopra R (2013) Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 160(4):487\u2013502. https:\/\/doi.org\/10.1111\/bjh.12172","journal-title":"Br J Haematol"},{"issue":"3","key":"5974_CR85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD et al (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 33(3):251\u2013257. https:\/\/doi.org\/10.1200\/JCO.2014.55.5714","journal-title":"J Clin Oncol"},{"issue":"5","key":"5974_CR86","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","volume":"107","author":"JA Burger","year":"2006","unstructured":"Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761\u20131767. https:\/\/doi.org\/10.1182\/blood-2005-08-3182","journal-title":"Blood"},{"issue":"5","key":"5974_CR87","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1 et al (2021) A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137(5):600\u2013609. https:\/\/doi.org\/10.1182\/blood.2020006578","journal-title":"Blood"},{"issue":"4","key":"5974_CR88","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3324\/haematol.2017.180505","volume":"104","author":"C Recasens-Zorzo","year":"2019","unstructured":"Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G et al (2019) Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica 104(4):778\u2013788. https:\/\/doi.org\/10.3324\/haematol.2017.180505","journal-title":"Haematologica"},{"issue":"7","key":"5974_CR89","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/15384047.2018.1449609","volume":"19","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang X, Liu Y, Sun C, Shi W, Huang H (2018) Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: a promising response and review. Cancer Biol Ther 19(7):549\u2013553. https:\/\/doi.org\/10.1080\/15384047.2018.1449609","journal-title":"Cancer Biol Ther"},{"issue":"10254","key":"5974_CR90","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"26","key":"5974_CR91","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory large B-Cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"5974_CR92","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"1","key":"5974_CR93","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","volume":"30","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink A-M, Tausch E et al (2024) Tislelizumab plus Zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med 30(1):240\u2013248. https:\/\/doi.org\/10.1038\/s41591-023-02722-9","journal-title":"Nat Med"},{"issue":"26","key":"5974_CR94","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R et al (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129(26):3419\u20133427. https:\/\/doi.org\/10.1182\/blood-2017-02-765685","journal-title":"Blood"},{"issue":"5","key":"5974_CR95","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","volume":"16","author":"EA Hawkes","year":"2015","unstructured":"Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16(5):e234\u2013e245. https:\/\/doi.org\/10.1016\/S1470-2045(15)70103-8","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05974-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:05:22Z","timestamp":1730855122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05974-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5974"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05974-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Review do not require ethical approval from the Ethics Committee of Lanzhou University Second Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}